Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 12,80€(+237,73%). Der Median liegt bei 12,80€(+237,73%).
Kaufen | 3 |
Halten | 4 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Chief Executive Officer and Co-founder, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:35 pm ET in New York, NY. A webcast of the panel discussion will be available on the “Even.» Mehr auf businesswire.com
Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?
Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.» Mehr auf zacks.com
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. “We shared exciting results this quarter from the PORTOLA trial, the first successful randomized study in treatment-refractory AIH,” said Chris Kirk, CEO and co-founder.» Mehr auf businesswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | - |
Nettoeinkommen | −15,30 Mio | 23,74% |
EBITDA | −14,75 Mio | 24,18% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 26,62 Mio€ |
Anzahl Aktien | 7,31 Mio |
52 Wochen-Hoch/Tief | 7,85€ - 3,09€ |
Dividenden | Nein |
Beta | 0,57 |
KGV (PE Ratio) | −0,40 |
KGWV (PEG Ratio) | 0,01 |
KBV (PB Ratio) | 0,30 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Name | Kezar Life Sciences Aktie |
CEO | Christopher J. Kirk |
Mitarbeiter | 55 |
Assets entdecken
Shareholder von Kezar Life Sciences Aktie investieren auch in folgende Assets